electroCore welcomes Dan Goldberger to its Board of Directors as CEO

– USA, NJ –  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Daniel S. Goldberger as CEO, effective October 1.

Mr. Goldberger brings to electroCore more than 35 years of experience in the biotechnology and medical technology industries. His areas of expertise include turnarounds, commercial execution, capital formation and product development, among others.

“I am pleased to welcome Dan to the electroCore team, and believe he is the ideal candidate to lead the company at this critical stage in its ongoing evolution,” said Carrie S. Cox, Chairman of the Board of Directors. “Dan’s vast experience leading turnarounds and reinvigorating growth across a diverse group of commercial-stage medical technology companies will serve us well as we work to extend the reach of our gammaCore noninvasive vagus nerve stimulation device in the U.S., and to new markets and indications. Over the course of his distinguished career, Dan has earned a reputation as a highly respected business leader with a track record of building commercially successful organizations, and the Board looks forward to his immediate contributions.”

“I would also like to thank Frank Amato for his leadership in navigating the company through a successful initial public offering and I wish him well in his future endeavors,” Ms. Cox concluded.

About Dan Goldberger

Prior to joining electroCore, Mr. Goldberger served as Executive Chairman of Repro Med Systems, Inc., a publicly-traded developer of home and specialty infusion products and had served as the company’s Chairman and interim Chief Executive Officer before that. At RMS, he helped transform the company as a rapidly growing drug delivery platform for chronic therapies in the home. Prior to RMS, Mr. Goldberger served as Chief Executive Officer of Milestone Medical, Inc., and as Director and Chief Executive Officer of Xtant Medical Holdings, Inc., a developer of orthobiologics and spinal fixation systems, from 2013-2017. Mr. Goldberger led Xtant’s restructuring by recruiting a world-class leadership team and expanding the company’s portfolio through the acquisition of complimentary products. Before Xtant, he served as Director and Chief Executive Officer of Sound Surgical Technologies from 2007-2013 and, before that, Xcorporeal, Inc. Earlier in his career, Mr. Goldberger held various positions at Glucon, Inc., OSI Systems, Ohmeda, Nellcor and Hewlett Packard.

“Throughout my career, I have been passionate about helping companies deliver novel medical technologies to patients with unmet needs while building shareholder value,” said Mr. Goldberger. “I believe in the broad potential applicability of vagus nerve stimulation across a wide range of indications, and I look forward to working with the highly motivated leadership team at electroCore to fully realize the potential of its proprietary gammaCore non-invasive VNS device.”Mr. Goldberger earned his B.S. in Mechanical Engineering from M.I.T, his M.S. in Mechanical Engineering from Stanford University and attended the Stanford Directors College.

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.

For more information : http://electrocore.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>